enta – Scalper1

AbbVie’s Hep C Regimen OK’d, 12-Week Cost $83,319

AbbVie’s hepatitis C regimen won FDA approval Friday, becoming the second entrant in what is already a huge market for interferon-free HCV treatments. The Viekira Pak will cost $83,319 for 12 weeks, in line with forecasts and undercutting Gilead Sciences’ (GILD) $94,500 for the same treatment length. The AbbVie (ABBV) regimen consists of three drugs: ombitasvir, paritaprevir (first developed by Enanta Pharmaceuticals (ENTA) and

Enanta Joins Big Leagues With Hepatitis C Drug

Jay Luly Enanta Pharmaceuticals CEO and president 57 years old B.S., organic chemistry, University of Illinois; Ph.D., organic chemistry, University of California, Berkeley Of note: Is on the board of trustees of the Boston Biomedical Research Institute Since it went public in March, little biotech Enanta Pharmaceuticals has been in the middle of a clash between giants. Enanta (ENTA) is the developer of ABT-450, a protease inhibitor that’s one of